Biocon - Global Healthcare Company
 
About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > ABOUT US
  Overview
  Businesses
  Fact Sheet
  Mission Vision Values
  People
  Quality
  CSR Policy
  History
  Awards
  Strategic Alliances
  Biocon in Malaysia
  
  Home
  
     
 

Businesses

Biocon has shaped its business into five key growth verticals with the aim to deliver sustainable long term value for patients, partners, healthcare systems across the globe.

- Small Molecules (APIs)
- Biosimilars
- Branded Formulations
- Novel Molecules

- Research Services

 
Click here to enlarge



Biocon’s fully integrated business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation. Our businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth. As we increase the complexity and scope of our own R&D and manufacturing operations, especially in new product discovery and development, we believe our custom and clinical research services will continue to offer important synergies.

 
Click here to enlarge


Syngene: Pre-Clinical Discovery

Biocon’s custom research organisation, Syngene, offers modular and integrated services in small and large molecule discovery and development. Offering meticulous IPR protection, we provide customised solutions to pharmaceutical, biotechnology, chemical, and agrochemical industries in the areas of chemistry, biology, process development and scale-up, formulation and analytical development, preclinical services, and GMP manufacturing for clinical supplies.

Clinigene: Clinical Research

Clinigene International Limited a subsidiary of Syngene, is a full-service Clinical Research Organization, it is an innovative provider of world-class clinical research solutions to global pharmaceutical and biotechnology companies. With state-of-the-art infrastructure and highly experienced clinical research professionals, Clinigene’s services span a broad spectrum of drug development activities including human pharmacology, bioanalytical research laboratory for small and large molecules, central laboratory, clinical operations, medical writing, medical monitoring, safety management & pharmacovigilance, clinical data management & biostatistics and regulatory services supporting early through late phase clinical development programs across a wide range of therapeutic areas. 

Biocon: Commercialisation

Biocon has an impressive track record of commercialisation capabilities. We have brought to market a considerable portfolio of biopharmaceuticals, led by our blockbuster Statins. The commercialisation of Insulin, Immunossuppressants and a range of Biogenerics demonstrates our highly advanced process development and manufacturing expertise. Under rapid progress are two challenging collaborative projects for the development of novel medicine, including Oral Insulin and T1h. Biocon also markets a basket of branded formulations in India, among them INSUGEN®, BIOMAb EGFR® and EPO.
 
     
  Quick links:
    Innovation Matrix
    Discovery Pipeline
    Fact Sheet
    Research & Development
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Clinigene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer | Authorised Users               © 2014, Biocon. All Rights Reserved